King's College London

Research portal

The AT(N) framework for Alzheimer's disease in adults with Down syndrome

Research output: Contribution to journalArticlepeer-review

Michael S. Rafii, Beau M. Ances, Nicole Schupf, Sharon J. Krinsky-McHale, Mark Mapstone, Wayne Silverman, Ira Lott, William Klunk, Elizabeth Head, Brad Christian, Florence Lai, H. Diana Rosas, Shahid Zaman, Melissa E. Petersen, Andre Strydom, Juan Fortea, Benjamin Handen, Sid O'Bryant

Original languageEnglish
Article numbere12062
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume12
Issue number1
DOIs
Published2020

Bibliographical note

Funding Information: Michael S. Rafii is supported by 1R61AG066543. Publisher Copyright: © 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of the Alzheimer's Association. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

Abstract

The National Institute on Aging in conjunction with the Alzheimer's Association (NIA-AA) recently proposed a biological framework for defining the Alzheimer's disease (AD) continuum. This new framework is based upon the key AD biomarkers (amyloid, tau, neurodegeneration, AT[N]) instead of clinical symptoms and represents the latest understanding that the pathological processes underlying AD begin decades before the manifestation of symptoms. By using these same biomarkers, individuals with Down syndrome (DS), who are genetically predisposed to developing AD, can also be placed more precisely along the AD continuum. The A/T(N) framework is therefore thought to provide an objective manner by which to select and enrich samples for clinical trials. This new framework is highly flexible and allows the addition of newly confirmed AD biomarkers into the existing AT(N) groups. As biomarkers for other pathological processes are validated, they can also be added to the AT(N) classification scheme, which will allow for better characterization and staging of AD in DS. These biological classifications can then be merged with clinical staging for an examination of factors that impact the biological and clinical progression of the disease. Here, we leverage previously published guidelines for the AT(N) framework to generate such a plan for AD among adults with DS.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454